Page 165 - PROGRAMME2018

10:45 O-242
Effects of high progesterone in in-vitro fertilization cycle on DNA methylation of endometrium receptivity markers during implantation window
Y. Xiong1, L. Hu2, T. Zhang3, H. Xu1, M. Wang2, Y. Sun2, C. Wang1
1The Chinese University of Hong Kong, Department of Obsetetrics and Gynaecology, Shatin- New Territories, Hong Kong
2the First Affiliated Hospital of Zhengzhou University, Reproductive Medical Center, Zhengzhou, China
3Shenzhen Zhongshan Urology Hospital, Shenzhen Key Laboratory of Reproductive Immunology for Peri-implantation- Fertility Centre, Shenzhen, China
Implantation enhancement by elective Cryopreservation of all viable Embryos (ICE): randomized controlled trial (RCT) comparing the two safest approaches in IVF/ICSI for high-responders
S. Santos-Ribeiro1,2, S. Mackens1, B. Popovic1, N.P. Polyzos1,3,4, A. Racca1,5, P. Drakopoulos1,6,7, M. De Vos1, H. Tournaye1, C. Blockeel1,8
1Universitair Ziekenhuis Brussel, Centre for Reproductive Medicine, Brussels, Belgium
2Santa Maria University Hospital, Department of Obstetrics- Gynaecology and Reproductive Medicine, Lisbon, Portugal
3Dexeus University Hospital, Department of Reproductive Medicine, Barcelona, Spain
4Faculty of Health University of Aarhus, Department of Clinical Medicine, Aarhus, Denmark
5University of Genoa, Academic Unit of Obstetrics and Gynecology, Genova, Italy
6Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy- Department of Surgical and Clinical Science, Brussels, Belgium
7University of Liège, Departement of Reproductive Medicine, Liège, Belgium
8University of Zagreb-School of Medicine, Department of Obstetrics and Gynaecology, Zagreb, Croatia
Oral dydrogesterone is an efficacious and safe alternative to intravaginal progesterone gel for luteal phase support in IVF: a randomized, open-label, multicenter, phase III study
G. Griesinger1, C. Blockeel2, A. Patki3, D.Z. Yang4, Z.J. Chen5, E. Kahler6, C. Pexman-Fieth7, H. Tournaye2
1University Hospital of Schleswig-Holstein, Department of Gynecological Endocrinology and Reproductive Medicine, Lübeck, Germany
2University Hospital of the Brussels Free University, Center for Reproductive Medicine, Brussels, Belgium
3Fertility Associates, Mumbai, India
4Sun Yat-Sen University, Department of Obstetrics and Gynecology, Guangzhou, China
5Shandong University, Department of Obstetrics and Gynecology, Shandong, China
6Abbott Laboratories GmbH, Clinical Development, Hannover, Germany
7Abbott GmbH & Co. KG, Women’s Health Medical Affairs and Clinical Development, Wiesbaden, Germany
FSHR type is a risk factor for developing ovarian hyper stimulation syndrome during in vitro fertilisation as observed in vivo and in vitro
H. Nenonen1, I. Lindgren1, E. Henic1, L. Bungum2, Y. Lundberg Giwercman1 1Lund University, Translational Medicin, Malmö, Sweden
2Copenhagen University Hospital, Department of fertility, Copenhagen, Denmark
11:00 O-243
11:15 O-244
11:30 O-245
FINAL PROGRAMME I BARCELONA, SPAIN – 1 TO 4 JULY 2018 165
SCIENTIFIC PROGRAMME WEDNESDAY, 4 JULY